Vyzulta Alternatives Compared
| Vyzulta (latanoprostene bunod) | Combigan (brimonidine / timolol) | Zioptan (tafluprost) |
|
|---|
| Vyzulta (latanoprostene bunod) | Combigan (brimonidine / timolol) | Zioptan (tafluprost) |
|
|||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Prescription only
Prescribed for Glaucoma - Open Angle, Glaucoma/Intraocular Hypertension. Vyzulta may also be used for purposes not listed in this medication guide. |
Prescription only
Prescribed for Glaucoma, Glaucoma/Intraocular Hypertension, Intraocular Hypertension. Combigan may also be used for purposes not listed in this medication guide. |
Prescription only
Prescribed for Glaucoma/Intraocular Hypertension, Glaucoma - Open Angle, Intraocular Hypertension. Zioptan may also be used for purposes not listed in this medication guide. |
Related suggestions Glaucoma/Intraocular Hypertension
|
|||||||||||||||||||||||
| More about Vyzulta (latanoprostene bunod) | More about Combigan (brimonidine / timolol) | More about Zioptan (tafluprost) | ||||||||||||||||||||||||
| Ratings & Reviews | ||||||||||||||||||||||||||
|
Vyzulta has an average rating of 6.6 out of 10 from a total of 13 ratings on Drugs.com. 62% of reviewers reported a positive effect, while 31% reported a negative effect. |
Combigan has an average rating of 4.9 out of 10 from a total of 25 ratings on Drugs.com. 40% of reviewers reported a positive effect, while 48% reported a negative effect. |
Zioptan has an average rating of 5.9 out of 10 from a total of 14 ratings on Drugs.com. 43% of reviewers reported a positive effect, while 36% reported a negative effect. |
||||||||||||||||||||||||
| Side Effects Experienced by Users Side effects are reported in Drugs.com user reviews and not clinically verified. | ||||||||||||||||||||||||||
|
View all Vyzulta side effects |
View all Combigan side effects |
View all Zioptan side effects |
||||||||||||||||||||||||
| Drug Class | ||||||||||||||||||||||||||
| Generic Availability | ||||||||||||||||||||||||||
| Pricing and Coupons * Prices are without insurance | ||||||||||||||||||||||||||
View all Vyzulta prices |
View all Combigan prices |
View all Zioptan prices |
||||||||||||||||||||||||
| Dosage Forms | ||||||||||||||||||||||||||
|
|
|
||||||||||||||||||||||||
| Brand Names | ||||||||||||||||||||||||||
|
N/A |
N/A |
N/A |
||||||||||||||||||||||||
| Half Life Drug half-life is the time required for plasma concentration to reduce to half its original value. | ||||||||||||||||||||||||||
|
N/A |
7 hours |
N/A |
||||||||||||||||||||||||
| CSA Schedule 1 View glossary of CSA terms | ||||||||||||||||||||||||||
|
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||||||||||||||||||
| Pregnancy Category | ||||||||||||||||||||||||||
|
Summary unavailable. See the full pregnancy warnings document. |
Category C
Risk cannot be ruled out
See the full pregnancy warnings document. |
Category C
Risk cannot be ruled out
See the full pregnancy warnings document. |
||||||||||||||||||||||||
| Drug Interactions | ||||||||||||||||||||||||||
|
A total of 7 drugs are known to interact with Vyzulta:
|
A total of 550 drugs are known to interact with Combigan:
|
A total of 6 drugs are known to interact with Zioptan:
|
||||||||||||||||||||||||
| Alcohol/Food/Lifestyle Interactions | ||||||||||||||||||||||||||
|
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
|
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
||||||||||||||||||||||||
| Disease Interactions | ||||||||||||||||||||||||||
|
No known disease interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
No known disease interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
|||||||||||||||||||||||||
| First Approval Date | ||||||||||||||||||||||||||
|
N/A |
October 30, 2007 |
N/A |
||||||||||||||||||||||||
| WADA Class View classifications | ||||||||||||||||||||||||||
|
N/A |
N/A |
|||||||||||||||||||||||||
| More Information | ||||||||||||||||||||||||||
| Patient Resources | ||||||||||||||||||||||||||
| Professional Resources | ||||||||||||||||||||||||||
| Related Treatment Guide | ||||||||||||||||||||||||||
1 The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
See also:
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.